You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

CLINICAL TRIALS PROFILE FOR ABEMACICLIB


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Abemaciclib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01394016 ↗ A Phase 1 Study of LY2835219 In Participants With Advanced Cancer Active, not recruiting Eli Lilly and Company Phase 1 2009-12-07 The purpose of this study is to determine a safe dose of LY2835219 to be given to participants with advanced cancer and to determine any side effects that may be associated with LY2835219 in this population. Efficacy measures will be used to assess the activity of LY2835219 in this population.
NCT01655225 ↗ A Study of LY3023414 in Participants With Advanced Cancer Active, not recruiting Eli Lilly and Company Phase 1 2012-07-31 The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer. The study will also explore the changes to various markers in blood cells and potentially tumor cells. Finally, the study will help document any antitumor activity this drug may have. In Part A of this study, participants with advanced/metastatic cancer (including lymphoma) will receive increasing doses of LY3023414. In Part B, LY3023414 will be explored in different types of cancer, including breast and lung cancer, lymphoma and mesothelioma.
NCT01739309 ↗ Study of LY2835219 for Mantle Cell Lymphoma Active, not recruiting Eli Lilly and Company Phase 2 2013-03-20 The purpose of this study is to estimate the disease control rate with abemaciclib for relapsed or refractory mantle cell lymphoma.
NCT01913314 ↗ A Study of Carbon-14-Labeled LY2835219 ([^14C]-LY2835219) in Healthy Participants Completed Eli Lilly and Company Phase 1 2013-08-01 This type of study is called a radiolabeled study. For this study, LY2835219 (study drug) has been specially prepared to contain radiolabeled carbon [^14C]. [^14C] is a naturally occurring radioactive form of the element carbon. This study will help understand how the drug appears in the blood, urine, and stool after it is administered. In addition, this study will also evaluate the safety and tolerability of a single dose of LY2835219 when given to healthy participants. Information about any side effects that may occur will also be collected. This study will last about 3 weeks for each participant, not including screening.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Abemaciclib

Condition Name

Condition Name for Abemaciclib
Intervention Trials
Breast Cancer 33
Metastatic Breast Cancer 19
Neoplasm Metastasis 8
Advanced Cancer 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Abemaciclib
Intervention Trials
Breast Neoplasms 77
Neoplasms 26
Carcinoma 16
Neoplasm Metastasis 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Abemaciclib

Trials by Country

Trials by Country for Abemaciclib
Location Trials
United States 793
China 96
Spain 81
Germany 60
Japan 58
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Abemaciclib
Location Trials
Texas 46
California 43
Massachusetts 41
New York 39
Florida 37
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Abemaciclib

Clinical Trial Phase

Clinical Trial Phase for Abemaciclib
Clinical Trial Phase Trials
Phase 4 5
Phase 3 17
Phase 2/Phase 3 1
[disabled in preview] 74
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Abemaciclib
Clinical Trial Phase Trials
Recruiting 78
Not yet recruiting 30
Completed 23
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Abemaciclib

Sponsor Name

Sponsor Name for Abemaciclib
Sponsor Trials
Eli Lilly and Company 96
National Cancer Institute (NCI) 18
Dana-Farber Cancer Institute 9
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Abemaciclib
Sponsor Trials
Industry 159
Other 120
NIH 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.